Amedisys (AMED) Tops Q2 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Amedisys Reports Second Quarter 2022 Financial Results and Updates 2022 Revenue Guidance
July 27, 2022 4:06 PM EDTBATON ROUGE, La., July 27, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2022.
Three-Month Periods Ended June 30, 2022 and 2021
Net service revenue decreased $6.3 million to $557.9 million compared to $564.2 million in 2021.Net income attributable to Amedisys, Inc. of $29.6 million compared to $80.1 million in 2021.Net income attributable to Amedisys, Inc. per diluted share of $0.91 compared to $2.43 in 2021.Adjusted... More
